Walter Klemp V bought $250k of MBRX
CEO and President at Moleculin Biotech, Inc.. 675,675 shares at an average of $0.37, traded Jun 23, 2025, filed Jun 23, 2025.
Score components
- +25RoleCEO
- +13Trade size$250k at market
- +10Relative to holdingsHoldings up 995%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +158.8%, 3m +48.9%, 6m -41.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001437749-25-021050, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 20, 2025 | MOption exercise Common Stock | +3,750 | - | - | 62,046 | Jun 23, 2025 |
| Jun 20, 2025 | FTax withholding Common Stock | -914 | $0.27 | $244 | 61,132 | Jun 23, 2025 |
| Jun 22, 2025 | MOption exercise Common Stock | +8,990 | - | - | 70,122 | Jun 23, 2025 |
| Jun 22, 2025 | FTax withholding Common Stock | -2,190 | $0.27 | $585 | 67,932 | Jun 23, 2025 |
| Jun 23, 2025 | POpen-market purchase Common Stock | +675,675 | $0.37 | $250k | 743,607 | Jun 23, 2025 |
| Jun 20, 2025 | MOption exercise Restricted Stock Unitsderivative | -3,750 | $0.00 | $0 | 391,446 | Jun 23, 2025 |
| Jun 22, 2025 | MOption exercise Restricted Stock Unitsderivative | -8,990 | $0.00 | $0 | 382,456 | Jun 23, 2025 |
| Jun 23, 2025 | POpen-market purchase Series E Warrantsderivative | -2,027,025 | - | - | 2,409,481 | Jun 23, 2025 |
Related signals
Other insiders at Moleculin Biotech, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | Moleculin Biotech, Inc. | Jonathan P. Foster Chief Financial Officer | $100k 270,270 shares | +1561% | |
| 55Moderate | Moleculin Biotech, Inc. | Jonathan P. Foster Chief Financial Officer | $20k 28,986 shares | +56% | |
| 48Moderate | Moleculin Biotech, Inc. | Robert E. George director | $10k 14,493 shares | +8678% | |
| 65Notable | Moleculin Biotech, Inc. | Walter Klemp V CEO and President | $130k 188,404 shares | +38% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.